Trial · NCT06702553
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
NCT06702553, Phase 3, Recruiting, Xijing Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass. Trials, record NCT06702553. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06702553
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT number
- NCT06702553
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 3,650 participants, estimated
- Lead sponsor
- Xijing Hospital
- Conditions
- Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
- Interventions
- Nitric Oxide Gas, Standard Care Arm
- First posted
- 2024-11-25
- Last updated
- 2026-05-29
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite outcome of death and major adverse events requiring intensive life supports | within 30 days after operation | It is composite outcome including: * all cause mortality; * ischemic events(myocardial infarction, ischemic stroke, and pulmonary embolism) , * Cardiac arrest that had been successfully resuscitated or new onset of acute cardiac failure (low output syndrome) requiring IABP, ECMO, left ventricular assist device, cardiac dysfunction need for large dose of inotrope support, ---Stage 3 AKI or Renal failure that required renal replacement therapy, * prolonged mechanical ventilation (\> 24h ), * re-sternotomy for any indication, * major arrhythmia ((Ventricular fibrilliation or ventricular tachycardia after weaning-off cardiopulmonary bypass, new onset atrial fibrillation requiring anticoagulant therapy or other intervention upon discharge from the hospital); * sepsis |
| Secondary | Total number of major adverse events (MAEs) | within 30 days after operation | Total number of major adverse events( MAEs) listed as the components of the primary outcomes. |
| Secondary | Incidence of the MAEs | within 30 days after operation | Incidence of the MAEs listed as the components of the primary outcomes. |
| Secondary | All AKI incidence | within 7 days of surgery | AKI incidence which will be diagnosed by KDIGO criteria |
| Secondary | Length of mechanical ventilation | within 30 days after operation | Length of mechanical ventilation in hours |
| Secondary | Readmission | within 30 days after operation | Readmission after hospital discharge |
| Secondary | Length of ICU stay | From the date of surgery until the date patient discharge from hospital, assessed up to 1 year | Length of postoperative ICU stay |
| Secondary | Length of postprocedural hospital stays | From the date of surgery until the date patient discharge from hospital, assessed up to 1 year. | Length of postprocedural hospital stays |
| Secondary | All cause 90 d mortality | within 90 days after operation | Death within 90 days after surgery for any reason |
| Secondary | All cause 1 year mortality | within 1 year after operation | Death within 1 year after surgery. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06702553
GET https://conductscience.org/api/trials/v1/NCT06702553/registered?page=2